共 50 条
- [21] Estimation of induction and maintenance costs of infliximab, adalimumab and certolizumab pegol in managing Crohn's disease [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S392 - S392
- [24] Certolizumab pegol in treatment of Crohn's disease with perianal lesions [J]. TERAPEVTICHESKII ARKHIV, 2018, 90 (04): : 50 - 54
- [25] Severe Crohn's disease symptoms are relieved by certolizumab pegol [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S471 - S471
- [27] CERTOLIZUMAB PEGOL IN CROHN'S DISEASE REFRACTORY TO INFLIXIMAB AND ADALIMUMAB [J]. ATENCION FARMACEUTICA, 2009, 11 (03): : 178 - 180
- [29] Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (08): : 866 - 874